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Cerebral cavernous malformations (CCM) are vascular le-
sions causing seizures and stroke. Mutations causing inactiva-
tion of one of three genes, ccm1, -2, or -3, are sufficient to induce
vascular endothelial cell defects resulting in CCM. Herein, we
show that loss of expression of the CCM1, -2, or -3 proteins
causes a marked increase in expression of the GTPase RhoA.
Live cell imaging with a RhoA-specific biosensor demonstrates
increased RhoA activity with loss of CCM1, -2, or -3, with an
especially pronounced RhoA activation in both the cytosol and
the nucleus with loss of CCM1 expression. Increased RhoA acti-
vation was associated with Rho kinase-dependent phosphoryla-
tion ofmyosin light chain 2. Functionally, loss ofCCM1, -2, or -3
inhibited endothelial cell vessel-like tube formation and extra-
cellular matrix invasion, each of which is rescued by chemical
inhibition or short hairpin RNA knockdown of Rho kinase. The
findings, for the first time, define a signaling network forCCM1,
-2, and -3 in CCM pathology, whereby loss of CCM1, -2, or -3
protein expression results in increased RhoA activity, with the
activation of Rho kinase responsible for endothelial cell dys-
regulation. The results define Rho kinase as a therapeutic target
to rescue endothelial cells from loss of CCM protein function.
Cerebral cavernous malformations (CCM)3 are clusters of
leaky, dilated capillaries in the central nervous system that
occur in 0.5% of the general population and up to 1.5% of the
Hispanic population (1). CCM frequently lead to clinical
sequelae such as hemorrhage, epilepsy, and neurological defi-
cits (1). The disease is associated with both germline and
somaticmutations in one of three genes, ccm1, -2, or -3 (2). The
three CCM proteins form a common complex, indicating that
they function coordinately (3, 4); each lacks defined catalytic
domains, indicating that they are scaffold- or adaptor-like pro-
teins for organization of protein complexes (3–5). The identical
disease phenotype produced upon loss of any one of the three
CCM proteins suggests that they coordinately regulate a com-
mon mechanism required for vascular integrity (3, 4, 6, 7).
It was recently shown that loss of endothelial cell expression of
CCM2 resulted in activation of the GTPase RhoA (7, 8). Crose et
al. (8) demonstrated thatCCM2knockdown in brainmicrovascu-
lar endothelial cells resulted in defective RhoA degradation
because of the dysregulation of Smurf1, a CCM2 binding partner,
and anubiquitin-protein isopeptide ligase (E3) that controlsRhoA
degradation. RhoA overabundance induced by loss of CCM2was
shownto increase cytoskeletal stability, inhibit vessel-like tube for-
mation, and increase endothelial cell monolayer permeability (7,
8). Herein, we show that loss of CCM1, -2, or -3 expression results
in a common phenotype associated with RhoA overexpression
and activation.WedefineROCKas a critical RhoAeffectorwhose
increased activation dysregulates endothelial cell function. ROCK
is activated by RhoA and phosphorylates several substrates,
includingmyosin light chain,myosin light chain phosphatase, and
LIM kinase for the regulation of actin cytoskeletal dynamics (9).
ROCK has also been shown to regulate vascular permeability
and has been a drug discovery target for regulation of vascular
bed diseases (10). Our findings show that ROCK inhibition res-
cues extracellular matrix invasion and vessel-like tube forma-
tion, two endothelial cell functions disrupted by loss of CCM
protein expression.
EXPERIMENTAL PROCEDURES
Establishment of Knockdown Cell Lines—Lentiviral gene-
specific shRNAs in pLKO.1 were obtained from the University
of North Carolina - Chapel Hill Lenti-shRNA Core Facility.
RhoA Biosensor—Imaging and image processing were per-
formed as described (11).
Tube Formation Assay and Live Cell Imaging—7.0  104
cells were incubated for 15 h onMatrigel (BD Biosciences) and
stained with rhodamine phalloidin as described previously (8).
Imaging was performed on either a Pathway (BD Biosciences)
or a Cellomics ArrayScan (Thermo Scientific). For live cell
imaging, six fields of cells were imaged via transmitted light
every 10 min for 15 h. Cellomics ArrayScan software was used
to quantitate mean tube area.
Statistical Significance—Where indicated, statistical signifi-
cance was calculated using the two-tailed Student’s t test. See
supplementalmaterial for additional Experimental Procedures.
RESULTS
Knockdown of CCM1, -2, or -3 Induces RhoA Overexpression
and Persistent RhoA Activity—Expression of each of the three
CCM proteins was selectively inhibited by shRNA knockdown
in endothelial cells (supplemental Fig. 1, A and B). Stable
knockdown of CCM1, -2, or -3 each resulted in 20–35-fold
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increases in RhoA expression relative toWTcells (Fig. 1A). The
finding that inhibition of CCM1, -2, or -3 protein expression
similarly caused marked increases in RhoA expression demon-
strates for the first time that the three CCM proteins function
coordinately to regulate RhoA protein levels; loss of any one
CCM protein causes an increase in RhoA expression. Previ-
ously, we showed that CCM2 knockdown resulted in dysregu-
lated Smurf1-mediated degradation of RhoA (8). The control of
RhoA protein levels requiring all three CCM proteins is con-
sistent with the requirement of a functional protein complex of
CCM1, -2, and -3 for regulating the degradation of RhoA.
A RhoA biosensor based on FRET, which has been exten-
sively characterized for measurement of activated RhoA in live
cells (11, 12), was used tomeasure the spatial dynamics of RhoA
activity in control and CCM1, -2, or -3 knockdown endothelial
cells. The overexpression of RhoA observed in CCM knock-
down cells results in a persistent activation of RhoA (Fig. 1, B
and C). In WT endothelial cells, RhoA activity is low and
observed primarily at the cell edge as described previously for
fibroblasts (11, 12). With shRNA knockdown of CCM2 or -3,
there is a significant increase in RhoA activity not only at the
cell edge but also in the cytoplasm and nucleus. When a popu-
lation of 50 single cells is imaged and averaged for FRET
intensity of the RhoA biosensor at the cell edge, cytoplasm, or
nucleus, the CCM1, -2, and -3 knockdown cells each have a
highly statistically significant increase in RhoA activation rela-
tive to control cells (Fig. 1D, see legend for p values). Strikingly,
RhoA activity is extremely high in CCM1 knockdown cells rel-
ative to control or CCM2 or -3 knockdown cells (Fig. 1B). Sta-
tistical analysis of a population of individual CCM1 knockdown
cells indicates an average of 1.62-, 2.33-, and 1.48-fold increase
in FRET intensity relative to WT cells for the cytoplasm,
nucleus, and cell edge, respectively (Fig. 1D).
These results show that regulation of RhoA protein expres-
sion is common to loss of any of the three CCMproteins. How-
ever, the pronounced RhoA activity in CCM1 knockdown cells
when compared with CCM2 or -3 knockdown indicates that
the CCM proteins are not simply in a common pathway but
have specific functions. AlthoughCCM2 binds Smurf1 for con-
trol of RhoA degradation, CCM1 appears to have a functional
role as a negative regulator of RhoA activity, and loss of CCM1
has a pronounced effect on RhoA activity, which is different
from the regulation of RhoA protein expression. Thus, the
FIGURE 1. RhoA abundance and activity are increased in shCCM1, -2, or -3
endothelial cells. A, Western blot showing that the abundance of RhoA in
shCCM1, -2, or -3 cells is increased 23-, 37-, and 28-fold relative to WT cells.
B, WT, shCCM1, -2, or -3 cells were infected with a FRET-based RhoA biosensor,
where activation of RhoA leads to FRET. The measured FRET signal has been
pseudocolored, where blue indicates low FRET and low RhoA activity, and
red/white indicates high FRET and high RhoA activity. RhoA activity is
increased at the cell edge (defined as 1.5-m width at the edge of the cell), the
cytoplasm, and the nucleus of shCCM1, -2, or -3 endothelial cells. C, enlarged
view of a representative control and shCCM2 knockdown cell showing active
RhoA at the cell edge, cytoplasm, and nucleus. D, bar graph showing the -fold
change in FRET intensity for the cytoplasm, nucleus, and cell edge of shCCM1,
-2, or -3 relative to WT control cells. Cytoplasm -fold FRET increase values
are: shCCM1 cells  1.62 (p value 4  1011), shCCM2 cells  1.16 (p value
0.001), shCCM3 cells  1.23 (p value 0.0003). Nuclear -fold FRET increases
are: shCCM1 cells  2.33 (p value 4.8  1011), shCCM2 cells  1.16 (p value
0.002), shCCM3 cells  1.23 (p value 0.0002). Cell edge -fold FRET increases
are: shCCM1 cells  1.48 (p value 5  109), shCCM2 cells  1.16 (p value
0.002), shCCM3 cells  1.20 (p value 0.002). Data represent the mean  S.E. for
a minimum of 25 cells in two independent experiments. Error bars, ***, p 
0.001, **, p  0.02, *, p  0.05.
REPORT: ROCK Inhibition Rescues CCM
APRIL 16, 2010 • VOLUME 285 • NUMBER 16 JOURNAL OF BIOLOGICAL CHEMISTRY 11761
CCMproteins organize a signaling network, not simply a path-
way for control of RhoA function.
ROCK2 Is Required for Increased Phosphorylation of Myosin
LightChain2 inCCM1, -2, or -3KnockdownCells—ROCK1and-2
are closely related kinases with overlapping but also distinct func-
tions (13). Both ROCK1 and ROCK2 bind activated GTP-RhoA
(13).MLC2 isphosphorylatedbyROCK1/2, andphospho-MLC2
is a measure of ROCK1/2 activity in cells (9, 13). MLC2 is
required for the control of actin cytoskeletal dynamics,
induction of stress fiber formation, and cell contraction (9),
whereby ROCK1/2 phosphorylation of MLC2 and MLC
phosphatase leads to increased cytoskeletal stability (13, 14).
We previously showed that stress fiber-associated phospho-
MLC2 was increased in brain microvascular endothelial cells
upon knockdown of CCM2 (8). Given the increased RhoA
activity observed in CCM1, -2, or -3 knockdown endothelial
cells (Fig. 1), we predicted that phosphorylation ofMLC2would
be increased with knockdown of each of the CCM proteins.
Phospho-MLC2 is indeed increased with loss of expression of
each of the three CCMproteins (Fig. 2). However, there is not a
linear relationship with the RhoA activity measured in Fig. 1
with knockdown of CCM1, -2, or -3 and the relative levels of
phospho-MLC2 measured by immunoblotting. This is consis-
tent with dysregulation of a regulatory network differentially
controlled by each CCMprotein. Nonetheless, control of RhoA
expression is a convergent regulatory function requiring each
CCM protein.
In mouse embryonic endothelial cells, ROCK2 is the func-
tionally predominant ROCK form and was targeted for shRNA
knockdown. Loss of ROCK2 expression reversed the increase in
phospho-MLC2 observed in each of the CCM protein knock-
down cell lines, demonstrating that ROCK2 stimulates the
phosphorylation of MLC2 in mouse embryonic endothelial
cells (Fig. 2).
Knockdown of CCM1, -2, or -3 Inhibits Endothelial Cell
Vessel-like Tube Formation and Invasion of Extracellular Matrix—
Knockdown of CCM1, -2, or -3 in endothelial cells results in inhi-
bition of extracellular matrix invasion and vessel-like tube forma-
tion (supplemental Fig. 2 and Fig. 3A). Even after 48 h, whereas
WT cells organize into a well formed tubule network, CCM1, -2,
and -3 knockdown cells fail to form vessel-like tubes (supple-
mental Fig. 3A). The findings define a commonphenotype for loss
of each of the three CCMproteins with inhibition of invasion and
vessel-like tube formation, providing quantitative assays to define
treatments to rescue the CCM pathology. Based on the common
inhibition of invasion and vessel-like tube formation and the
increased ROCK2-dependent increase in phospho-MLC2 with
knockdownof eachCCMprotein,we reasoned that ROCK2was a
therapeutic target to reverse the CCMphenotype.
CCM1, -2, or -3 Knockdown Pathology Is Rescued by Inhibi-
tion of ROCK—Relevant to rescue of the CCM pathology, we
previously demonstrated that the small molecule ROCK
inhibitor Y-27632 (Calbiochem) rescued inhibition of endo-
thelial cell migration resulting from shRNA knockdown of
CCM2 in a scrape wound-healing assay with brain microvas-
cular endothelial cells (8). Y-27632 or shRNA knockdown
of ROCK2 was used to test the role of ROCK in rescuing
loss of endothelial cell invasion of extracellular matrix
(supplemental Fig. 2). Importantly, knockdown of CCM1, -2,
or -3 did not affect ROCK2 expression, nor did knock-
down of ROCK2 affect expression of CCM1, -2, or -3
(supplemental Fig. 4). Inhibition of extracellular matrix
invasion resulting from CCM1, -2, or -3 knockdown was
rescued by either loss of ROCK2 expression or treatment of
cells with Y-27632 (supplemental Fig. 2). CCM1 knockdown
cells were only weakly rescued by Y-27632 but strongly res-
cued by shRNA knockdown of ROCK2. This may in part be
due to the time-dependent reversal of the strong CCM1
knockdown phenotype with Y-27632 (Figs. 1 and 3B, and see
below).
In vessel-like tube formation assays, time-lapse imaging of con-
trol versus CCM1, -2, or -3 knockdown endothelial cells showed
that knockdown of ROCK2 or treatment of cells with Y-27632 to
inhibit ROCK activity rescued vessel-like tube formation for each
of the three CCM protein knockdown endothelial cell lines
(supplemental Fig. 3B andFig. 3,B–D).Analysis ofmultiple vessel-
like tube formation assays indicated that rescue of the CCM
pathology, as measured by the increase in mean tube area, was
greater with shRNA knockdown of ROCK2when compared with
Y-27632 (Fig. 3E and supplemental Fig. 3B). Analysis of the time-
lapse images indicated that the onset of vessel-like tube formation
was delayed several hours with treatment of CCM1, -2, or -3
knockdown cells with Y-27632 when compared with vessel-like
tube formation with control or ROCK2 knockdown cells (Fig. 3,
B–D, and supplementalMovies 1–3). This finding is similar to the
reduced rescue of extracellular matrix invasion in CCM1 knock-
down cells treated with Y-27632 when compared with shROCK2
FIGURE 2. Western blots showing an increase in phospho-MLC2 in
shCCM1, -2, or -3 endothelial cells, which is lost upon shRNA knockdown
of ROCK2. The bar graph shows the densitometric quantitation of band
intensity. The abundance of phospho-MLC2 (P-MLC2) in shCCM1, -2, or -3 cells
increases 1.7-, 3.0-, and 1.6-fold, respectively, relative to control pLKO.1 cells
(the graph represents an average of three independent experiments). Upon
shRNA knockdown of ROCK2, this abundance decreases below detectable
levels, 50 and 90%, respectively, for shCCM1, -2, or -3 relative to pLKO.1. Error
bars, ***, p  0.001, **, p  0.02, *, p  0.05. Line indicates two separate blots.
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(supplemental Fig. 2) and is likely due to the time required for
chemical inhibition of ROCKand reversal of the ROCK-mediated
changes in cellular physiology.
Y-27632 Treatment Induces Endothelial Cell Shape Changes
Required for Vessel-like Tube Formation in CCM1, -2, or -3
Knockdown Cells—Loss of ROCK2 expression by targeted
shRNA knockdown inhibits the activated RhoA stimulation of
MLC2 phosphorylation (Fig. 2). Hence, rescue of the in vitro
CCM pathology caused by loss of one of the three CCM pro-
teins, asmeasured by vessel-like tube formation and invasion of
extracellular matrix, is essentially complete, and the cells
behave similar to control cells. Y-27632 rescue of the CCM
pathology is similar to shRNA knockdown of ROCK2. Pharma-
cological ROCK2 inhibition reverses pathways controlled by
ROCK2 that contribute to the CCM1, -2, or -3 knockdown
phenotype. In a subpopulation of CCM1, -2, or -3 knock-
downs, incubation with Y-27632
induces a time-dependent change
in cell shape involving cell flat-
tening and the extension of
multiple membrane protrusions
(supplemental Fig. 5). The cell
shape changes are evident after
a 1-h treatment with Y-27632,
and by 4 h, these cells are forming
nucleation centers for the initia-
tion of tube formation (supple-
mental Fig. 5, arrowhead). CCM
knockdown cells in the absence of
Y-27632 areunable toundergo signif-
icant cell shape change and extend
only small filopodial-like structures
(supplemental Fig. 5, arrows). In con-
trast, pLKO.1knockdowncells donot
undergo the shape changes induced
by Y-27632 because ROCK2 is not
activated and driving constitutive
RhoA control of the actin cytoskele-
ton (13, 14). Consistent with these
observations is the fact that loss of
ROCK2 expression in both control
cells and CCM protein knockdown
cells causes formation of well defined
vessel-like tubes 4 h after initiating
the assay (Fig. 3, B–D, and sup-
plemental Fig. 3B). The findings indi-
cate that ROCK2 actively drives the
CCM pathology characterized by
inhibition of invasion of extracellular
matrixandvessel-like tube formation.
DISCUSSION
The three ccm genes encode scaf-
fold or adaptor proteins capable of
forming a CCM1-2-3 protein com-
plex for organization of proteins
involved in regulating the cytoskele-
ton (3, 5).Thus, themolecular basis of
CCM is fascinating in that loss of function of a scaffold or adaptor
protein is sufficient to develop the pathology (5–7). The function
of CCM proteins was further elucidated by the discovery that
RhoAbecomes overexpressedwith loss ofCCM2expression (7, 8)
and that CCM2 regulates RhoA protein level by controlling its
degradation (8).We have now shown that CCM1 and -3 proteins
in addition to CCM2 are required for regulation of RhoA protein
levels, and loss of CCM1, -2, or -3 each results in the pronounced
increase in expression of RhoA. This result supports the critical
role of theCCMprotein complex in controlling RhoA expression.
The RhoA biosensor allowed measurement of live cell images for
RhoA activity in control and CCM1, -2, and -3 knockdown cells.
Clearly, RhoA activity is increased with loss of CCM1, -2, or -3
proteins, and the increased RhoA activity results in changes in
regulation of ROCKand the cytoskeleton. The pronouncedRhoA
activity with CCM1 knockdown strongly suggests that CCM1 has
FIGURE 3. ROCK inhibitor Y-27632 and ROCK2 shRNA rescue tube formation in shCCM1, -2, or -3 endo-
thelial cells. A, knockdown of CCM1, -2, or -3 results in loss of tube formation. The image is a nine-panel
montage of 10 frames, and the bar represents 300 m. B, tube formation in shCCM1 cells can be rescued with
Y-27632 (Y) or shROCK2 (R). Frames are from supplemental Movie 1 taken at 0, 1, 3, 5, and 15 h after the start
of treatment with Y-27632. The bar represents 100 m. The image is a single 10 field. C, tube formation rescue
in shCCM2 cells by shROCK2 or Y-27632. D, tube formation rescue in shCCM3 cells by shROCK2 or Y-27632. E,
the bar graph represents the mean tube area of pLKO.1 and shCCM1, -2, and -3 cells, normalized to pLKO.1. The
data are the means  S.E. of six frames from at least three independent experiments. Error bars, ***, p  0.001,
**, p  0.02, *, p  0.05.
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a function controlling a Rho guanine nucleotide exchange factor
orRhoGTPase-activatingprotein.Thisdifference suggests a func-
tion specific forCCM1relative toCCM2or -3.However, the effect
of CCM1 loss of expression was not generally different fromwhat
was observed with loss of CCM2 or -3 expression for changes in
phospho-MLC2 levels or dysregulation of invasion or vessel-like
tube formation.These findings indicate there is not simply a linear
pathway of RhoA expression-ROCK activation-phosphorylation
of MLC2. Rather, the CCM proteins represent a dynamic regula-
tory network where they are sometimes in a complex but other
times found in different cellular locations (4, 5), consistent with
commonbut also distinct functions.Wehave proposed thatCCM
proteins localize signaling complexes to specific cellular loca-
tions associated with actin reorganization (3, 8). This would
suggest that CCM proteins spatially control RhoA degradation
for regulating specific physiological functions. Interestingly,
activation of RhoGTPases andROCKhas also been observed in
Smith-Lemli-Opitz syndrome (15), suggesting that dysregula-
tion of this signaling axis has major pathophysiological impli-
cations in different human diseases.
Surgical resection is currently the standard treatment for
symptomaticCCM, a highly invasive procedurewith significant
risk to the patient (16). In addition, lesions located in critical
areas such as the brainstem or basal ganglia are more likely to
exhibit a poor natural history, yet no treatment exists because
they are surgically inaccessible. The discovery that inhibition of
ROCK, a kinase activated by RhoA, is able to rescue dysregu-
lated endothelial cell physiology resulting from loss of CCM1,
-2, or -3 expression provides, for the first time, a pharmacolog-
ical approach using a small molecule kinase inhibitor for treat-
ment of CCM. The function of RhoA and ROCK in promoting
vascular permeability is consistent with the dysregulated
RhoA-ROCK signaling axis being important in promoting
CCM pathology. Thus, ROCK inhibitors are clearly potential
therapeutics for the treatment of CCM. Studies have shown
that two ROCK inhibitors, Fasudil and Y-27632, are reasonably
well tolerated in animals (17). In fact, Fasudil has been used in
Japan for treatment of cerebral vasospasm following subarach-
noid hemorrhage since 1995 (18), indicating that ROCK inhib-
itors can be tolerated in humans.
Given that the RhoA-ROCK signaling network is clearly dys-
regulated in CCM, there is still much to learn about the RhoA
activation and inactivation cycle and how it is dysregulated in
CCMendothelial cells.Questions also remain regarding theCCM
protein complex and control of signaling networks including the
potential involvement of additional kinases that could contribute
to the CCM pathology and be pharmacologically targeted for
treatmentofCCM.Forexample,MEKK3, aMAP3Kthat regulates
ERK5, c-Jun N-terminal kinase (JNK), and NFB, is in the CCM
protein complex and is important for regulating responses to
inflammatory cytokines such as interleukin-1 (IL-1) (3, 19). Signif-
icantly, it appears that a pharmacological small molecule treat-
ment to control CCM is a real possibility.
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